In conclusion, this prospective, observational study showed that a smaller number of coexisting mutations, earlier stage, sex (female), and younger age were associated with longer RFS, while EGFR mutation positivity was significantly associated with improved OS, as well as earlier stage, a smaller number of coexisting mutations, and younger age, in resected NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.